4TX

5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid

4TX as a free ligand exists in 1 entry. Examples include: 5BOJ

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
Identifiers5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
FormulaC15 H22 O3
Molecular Weight250.33
TypeNON-POLYMER
Isomeric SMILESCc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
InChIInChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
InChIKeyHEMJJKBWTPKOJG-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count40
Chiral Atom Count0
Chiral Atomsn/a
Bond Count40
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01241 Different stereochemistry
NameGemfibrozil
Groupsapproved
DescriptionA lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established. [PubChem]
Synonyms
  • 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
  • Gemfibrozil
  • Gemfibrozilo
Brand Names
  • Apo-gemfibrozil
  • Apo-gemfibrozil Cap 300mg USP
  • Dom-gemfibrozil
  • Gemfibrozil
  • Gemfibrozil Cap 300mg
Affected OrganismHumans and other mammals
IndicationFor treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.
PharmacologyGemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately).
Mechanism of actionGemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL.
Route of administrationOral
Categories
  • Acids, Acyclic
  • Antimetabolites
  • Benzene Derivatives
  • Butyrates
  • Carboxylic Acids
ATC-CodeC10AB04
AHFS-Code24:06.06
CAS number25812-30-0

Drug Targets

NameSequence SearchPharmacological ActionActions
Peroxisome proliferator-activated receptor alphaMVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFG...yesagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682